Skip to main
IBRX
IBRX logo

ImmunityBio (IBRX) Stock Forecast & Price Target

ImmunityBio (IBRX) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ImmunityBio has demonstrated strong financial growth, with Q4 2024 net product revenue increasing by 21% to $7.2 million, driven by robust sales of ANKTIVA following its FDA approval. The product candidate has shown promising long-term durability and efficacy, as reflected in previously reported disease-free survival rates and improved complete response rates in recent trials. Additionally, the company's strategic collaborations, regulatory progress in Europe, and projected revenue growth from ANKTIVA, anticipated to reach $137.4 million by 2025 and $4.3 billion by 2034, further enhance the positive outlook for ImmunityBio’s stock.

Bears say

ImmunityBio has experienced ongoing operating losses since its inception, with an outlook suggesting that profitability may remain unattainable for several more years, which raises concerns about the sustainability of its financial model. Additionally, the company's debt and revenue interest liability are likely to strain cash flows and hinder its ability to secure further capital, potentially limiting growth opportunities. Further complicating its prospects, the company faces skepticism regarding the regulatory approval process and manufacturing capabilities, along with a declining complete response rate for its therapies, which collectively contribute to a negative sentiment around its stock.

ImmunityBio (IBRX) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ImmunityBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ImmunityBio (IBRX) Forecast

Analysts have given ImmunityBio (IBRX) a Strong Buy based on their latest research and market trends.

According to 6 analysts, ImmunityBio (IBRX) has a Strong Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ImmunityBio (IBRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.